Xelaglifam, a novel GPR40/FFAR1 agonist, exhibits enhanced β-arrestin recruitment and sustained glycemic control for type 2 diabetes | Multispan, Inc

Xelaglifam, a novel GPR40/FFAR1 agonist, exhibits enhanced β-arrestin recruitment and sustained glycemic control for type 2 diabetes

Xelaglifam, a novel GPR40/FFAR1 agonist, exhibits enhanced β-arrestin recruitment and sustained glycemic control for type 2 diabetes

GPCR Target: Multiscreen™ TR-FRET cAMP 1.0 No Wash Assay Kit

Authors: Jongmin Yoon, et al.

Journal: Biomedicine & Pharmacotherapy, Volume 177, 2024, 117044, ISSN 0753-3322.

Year Published: 2024

Leave a Reply Cancel reply